Navigation Links
Cepheid Schedules Teleconference and Webcast for First Quarter 2008 Results
Date:4/7/2008

SUNNYVALE, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) will announce financial results for the first quarter 2008 after the markets close on Thursday, May 1, 2008. The announcement will be followed by a live conference call and webcast that afternoon at 4:30 p.m. Eastern Time.

John Bishop, Chief Executive Officer, Andy Miller, Senior Vice President, Chief Financial Officer and Michael Myhre, Vice President, Corporate Controller, will host the conference call to discuss Cepheid's financial results and business highlights. David Persing M.D., Ph.D., Executive Vice President and Chief Medical and Technology Officer, and Robert Koska, Senior Vice President Worldwide Commercial Operations, will also participate in the Q-and-A portion of the call.

Interested participants and investors may access the teleconference call by dialing 888-679-8018 (U.S./Canada) or 617-213-4845 (international), participant code 93009314. A telephonic replay will be available for seven days beginning at 6:30 p.m. Eastern Time. Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international); participant code 25802805. Callers can also pre-register for the call through the following link: https://www.theconferencingservice.com/prereg/key.process?key=PYWVXBAML

The webcast of the call can be accessed on the Investor section of Cepheid's Web site at http://www.cepheid.com under Investors: Events: Webcasts and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download, and install any necessary software. After the live webcast, a replay will remain available in the Investors section of Cepheid's Web site for 90 days.

About Cepheid

Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demand molecular diagnostics company that develops, manufactures, and markets fully- integrated systems for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080129/LATU101LOGO)


'/>"/>
SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
2. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
3. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
4. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
5. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
6. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
7. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
8. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
9. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
10. Cepheid Reports Fourth Quarter and Full Year 2007 Results
11. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2019)... ... ... a German Shepherd, was demonstrating signs of osteoarthritis in April 2019. He was lame ... his willingness to play were normal, it was clear that he was in pain. , ... Hospital and Referral Center in San Diego, California. Dr. Mullen is an experienced ...
(Date:11/2/2019)... , ... October 31, 2019 , ... ... Adaptive Biotechnologies in a live webinar on Friday, November 15, ... immuno-oncology. , Immunosequencing, the science of profiling T-cell receptors (TCRs) and B-cell ...
(Date:10/30/2019)... ... October 30, 2019 , ... While using cold plasma ... students at South Dakota School of Mines & Technology are exploring new ... healthy cells alive. , If successful, the technique would prove to be a ...
(Date:10/29/2019)... ... ... CaroGen Corporation , a biotechnology company, today announced three distinguished additions to ... MD, of Brown University , Dr. Steve Projan, PhD, FAAM, formerly of ... Wayne State University, formerly a professor at Yale University School of Medicine ...
Breaking Biology Technology:
(Date:11/19/2019)... ... 2019 , ... The inaugural Cell & Gene Therapy Day takes place February ... event will be chaired by Dr Aiman Shalabi, VP R&D, Cell and Gene Therapies ... are witnessing significant innovation in cell and gene therapies, and we are at a ...
(Date:11/12/2019)... GREEN, Ohio (PRWEB) , ... ... ... Engineered Products , a global leader in the design and manufacturer of ... selection of seating and adjustable footrests compliant with Healthier Hospital Initiative guidelines. ...
(Date:11/9/2019)... ... 2019 , ... SiteSeer Technologies, creator of SiteSeer Professional retail site selection software, ... of SiteSeer. The boutique real estate developer of single and multi-tenant buildings on sites ... its own analysis of markets. , Geoffrey Kerth, manager of GPK Acquisitions, says ...
Breaking Biology News(10 mins):